## **Table of contents**

1		CTION	
		ICAL GENETICS AND THE GENOMIC REVOLUTION	
	1.2 GEN	ETIC DISORDERS: AN OVERVIEW	1
	1.3 CON	VENTIONAL DIAGNOSTICS AND THE DIAGNOSTIC ODYSSEY	2
	1.4 SAN	GER AND THE HUMAN GENOME PROJECT	3
	1.5 THE	NEXT-GENERATION-SEQUENCING TECHNOLOGY REVOLUTION	4
		MODALITIES USED IN THIS STUDY	
	1.6.1 W	hole-Exome Sequencing (WES)	5
	1.6.2 Tr	uSight TM One Sequencing Panel: "The Mendeliome"	6
	1.7 AN C	VERVIEW OF SYNDROMIC SHORT STATURE SYNDROMES	
	1.8 THE	SKELETAL DYSPLASIAS	8
	1.8.1 Os	steogenesis Imperfecta	9
	1.8.1.1	Type I Collagen biosynthesis	10
	1.8.1.2	Defects in osteoblast development and the WNT-signalling pathway	11
	1.8.2 Ur	ndiagnosed Skeletal Dysplasias	14
	1.9 SELE	ECTED SHORT STATURE SYNDROMES	14
	1.9.1 Du	ıbowitz Syndrome	
	1.9.1.1	C.elegans as a model organism to study DNA damage response	
	1.9.2 Ur	ndiagnosed Short Stature	
2			
Z			
3	METHOD	S AND MATERIALS	20
	3.1 PATI	ENT RECRUITMENT AND INFORMED CONSENT	20
		hics approval	
		tients and Families	
	3.2 MAT	ERIALS	20
	3.2.1 Re	agents/Buffers/Enzymes	20
		ts	
	3.2.3 Ar	ntibodies	21
		imers	
	3.2.5 W	eb resources	22
	3.3 MET	HODS	22
	3.3.1 Nu	ıcleic acid analysis	
	3.3.1.1	DNA extraction	
	3.3.1.2	Polymerase Chain Reaction (PCR)	22
	3.3.1.3	Agarose gel electrophoresis and gel extraction	23
	3.3.1.4	Sanger sequencing	23
		olecular cloning	23
	3.3.2.1	Exon trapping	23
	3.3.2.2	Generation of MESDC2 mutant constructs	23
	3.3.3 NO	GS technologies	24
	3.3.3.1	Whole-Exome Sequencing (WES)	24
	3.3.3.2	TruSight <sup>™</sup> One Panel: Mendeliome	
	3.3.3.3	NGS Data Analysis	
	3.3.3.4	NGS Data Filtering strategy	
	3.3.3.5	Variant validation and curation	25
	3.3.4 Ce	ll culture	
	3.3.4.1	Cell proliferation	
	3.3.4.2	USP20-deletion mutant HAP1 cell-line	
	3.3.4.3	Cell transfection	
	3.3.4.4	Cell treatment	
	3.3.5 Im	munological Methods	26
	3.3.5.1	Western blot	
	3.3.5.2	Immunofluorescent (IF) staining	
	3.3.6 <i>C</i> .	elegans-specific methods	
	3.3.6.1	Solutions / media / strains	
	3.3.6.2	Synchronization of worm cultures	27



2262	0:1	••
3.3.6.3 3.3.6.4	0 7 8 71 8	28
3.3.6.5		
3.3.6.6		
	ATISTICS	
	SLECULAR GENETIC TESTING	
	ELETAL DYSPLASIAS	
	Osteogenesis imperfecta: Novel Genes	
4.2.1.1	0 1	
4.2.1.2		37
	Osteogenesis imperfecta: Novel Candidate Gene	30
4.2.2.1		
	skeletal dysplasias: Novel Candidate Genes	
4.2.3.1	ERII: A candidate gene for a novel autosomal recessive SEMD syndrome associated v	
	ous syndactyly and early lethality	
4.2.3.2		
pseudo	achondroplasia	42
4.2.3.3	KDM5C: A novel candidate gene for Angel-Shaped-Phalango-Epiphyseal Dysplasia?.	43
4.2.4	Skeletal Dysplasias: Novel mutations and further delineation of the clinical spectrum	45
4.2.4.1	PAM16: A novel mutation in a patient with a milder phenotype and longer survival	
4.2.4.2	IARS2: Confirmation of CAGSSS syndrome and the proposal of novel bone dysplasia	
family	related to mitochondrial dysfunction	48
4.2.4.3	Metatarsal bony syndactyly in two fetuses with Smith-Lemli-Opitz syndrome: an unde	r-
recogn	ized part of the clinical spectrum	50
4.2.4.4	Severe spondylar dysplasia in a patient with a COL10A1 mutation	53
4.2.4.5	A novel COL10A1 mutation underlies SMD corner fracture type	54
	sis NDROMIC SHORT STATURE SYNDROMES	
	Novel Genes Underlying Syndromic Short Stature	
4.3.1.1	Mutations in CKAP2L cause Filippi syndrome	
	Novel Candidate Genes For Dubowitz Syndrome	
4.3.2.1	First evidence implicating a <i>de novo</i> mutation in <i>USP20</i> in Dubowitz syndrome	
4.3.2.2		
	ype and the Dubowitz syndrome phenotype in a single patient	
4.3.2.3		
4.3.2.4		
syndro	me	72
4.3.3	Syndromic Short Stature Syndromes: Novel Mutations and Further Delineation of The Clinic	cal
Spectrum		73
4.3.3.1	Novel mutation in TELO2: severe expression of You-Hoover-Fong syndrome	73
4.3.3.2		
	ephaly	
4.3.3.3	Novel mutation in VPS13B in an Algerian family and intra-familial variability in Cohe	
	me	
	E MENDELIOME STUDY	
4.4.1 N	Mendeliome-Testing Process	79
	Mutation Mining And The "MM-Team" Workflow	
	atients and Mutations	
	Novel Genes	
4.4.4.1	AP3B2: A novel gene underlying microcephaly	
4.4.4.2		
4,4.4.3	RNF213: A novel gene underlying systemic sclerosis	
	Novel Phenotypes	86
4.4.5.1	USP9X: X-linked dominant Syndromic Intellectual Disability	8/
4.4.5.2	BMP1: Syndromic short stature with growth hormone deficiency	
4.4.5.3	PMM2: Micro-lissencephaly	ბბ

	4.4.5.4 RARS2: Severe ID with cerebral atrophy	89		
	4.4.6 Microdeletion Syndromes	89		
	4.4.6.1 M12: Microdeletion Chromosome 18	89		
	4.4.6.2 M13: Microdeletion Chromosome 7			
	4.4.6.3 M14: Microdeletion Chromosome X (ACSL4)	90		
	4.4.7 A Family with 2 Children with Different Genetic Disorders			
	4.4.8 Results from the Beta Test of the Updated Mendeliome			
	4.4.9 Novel Mutations	92		
5	DISCUSSION	93		
	5.1 NGS ENDS THE DIAGNOSTIC ODYSSEY			
	5.2 NOVEL GENES FOR OSTEOGENESIS IMPERFECTA			
	5.2.1 Autosomal Recessive Mutations In MESDC2 Cause Osteogenesis Imperfecta	94		
	5.2.2 SEC24D: A Novel Autosomal Recessive OI Gene	97		
	5.2.3 HYAL4: An Interesting Novel Candidate Gene For Autosomal Recessive OI	99		
	5.3 SKELETAL DYSPLASIAS			
	5.3.1 ERII: A Novel Mechanism Implicated In Skeletal Dysplasia	99		
	5.3.2 MEGF8: A Novel Candidate For An Autosomal Recessive SEMD Resembling			
	Pseudoachondroplasia	100		
	5.3.3 Implications of De Novo Variant in KDM5C – A Novel ASPED Gene?	101		
	5.3.4 Patient with a Novel Mutation in PAM16 Shows That SMDMDM Is Not Always Assoc	iated With		
	Early Demise	102		
	5.3.1 Confirmation of CAGSSS Syndrome and a New Mitochondrial Bone Dysplasia Family	103		
	5.3.2 Confirmation of Bony Syndactyly as an Under-Recognized Part of the SLOS Clinical			
	Spectrum.			
	5.3.3 Novel Findings In Patients With Mutations In COL10A1			
	5.3.1 AMDM: Correct Diagnosis Facilitates Accurate Genetic Counselling			
	5.3.2 B3GALT6: Ending The 15 Year Diagnostic Odyssey	109		
	5.4 SHORT STATURE SYNDROMES			
	5.4.1 Mutations In CKAP2L Cause Filippi Syndrome	110		
	5.4.2 Dubowitz Syndrome: Genetic Heterogeneity The Rule Rather Than The Exception			
	5.4.2.1 USP20: A novel player in DNA damage repair			
	5.4.2.2 FAT1/FYB: Digenic inheritance may explain complex phenotype			
	5.4.2.3 KREMENI: A further underling cause for Dubowitz syndrome?			
	5.4.2.4 DYRK1A: A novel mutation in a patient with a clinical diagnosis of Dubowitz sy			
	5.4.3 Novel Mutations in TELO2 and expanding the YHFS clinical spectrum	116		
	5.4.4 Further Novel Mutations for Syndromic Short Stature			
	5.5 THE MENDELIOME STUDY	118		
	5.6 AFTER GENE IDENTIFICATION – NEXT STEPS?	120		
6	CONCLUSION AND OUTLOOK	121		
-	REFERENCES			
7				
8	ACKNOWLEDGEMENTS	132		
9	APPENDICES			
	9.1 APPENDIX 1 : TABLE A1			
	9.2 APPENDIX 2 : TABLE A2			
	9.3 APPENDIX 3: SCIENTIFIC PRESENTATIONS BASED ON THIS PHD			
	9.4 CURRICULUM VITAE/LEBENSLAUF ERROR! BOOKMARK NOT			
	9.5 ERKLÄRUNG	149		